Evaluation of early and late toxicities in chemoradiation trials.
about
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networksENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy)Standardized data collection to build prediction models in oncology: a prototype for rectal cancer.Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.Methodologies for localizing loco-regional hypopharyngeal carcinoma recurrences in relation to FDG-PET positive and clinical radiation therapy target volumes.Assessing feasibility, compliance and toxicity of concomitant chemo-radiotherapy in head and neck cancers in the Northern Territory: initial experience and challenges.In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer.Normal tissue studies in radiation oncology: A systematic review of highly cited articles and citation patterns.Patient-derived xenograft models in gynecologic malignanciesShort-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323Stereotactic body radiotherapy as primary therapy for head and neck cancer in the elderly or patients with poor performance.[Swallowing disorders after partial laryngectomy. Prevalence and predictors].Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience.Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy.Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Emerging drugs to treat squamous cell carcinomas of the head and neck.Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancerA spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature reviewProspective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT study.Prediction of Acute Radiation Mucositis using an Oral Mucosal Dose Surface Model in Carbon Ion Radiotherapy for Head and Neck Tumors.Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues.Personalized radiotherapy: concepts, biomarkers and trial designRandomized controlled trials in health technology assessment: overkill or overdue?A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis.Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology GroupIntensity-modulated radiation therapy using static ports of tomotherapy (TomoDirect): comparison with the TomoHelical modeThe status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology)Long-term disease-specific and cognitive quality of life after intensity-modulated radiation therapy: a cross-sectional survey of nasopharyngeal carcinoma survivorsLong-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer.Therapy and prophylaxis of brain metastases.Guidelines for preclinical and early phase clinical assessment of novel radiosensitisersOral cancers: supportive care issues.Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health.Reirradiation for recurrent head and neck cancer.Fluorine-19 Labeling of Stromal Vascular Fraction Cells for Clinical Imaging Applications.Outcomes in Advanced Head and Neck Cancer Treated with Up-front Neck Dissection prior to (Chemo)Radiotherapy.Risk of swallowing-related chest infections in patients with nasopharyngeal carcinoma treated with definitive intensity-modulated radiotherapy.
P2860
Q26991945-C271C371-672E-4FFA-8C73-C8838CD4B7B5Q27007797-BB5249F2-E5A3-4B43-8817-B43FBAE3BA4EQ31032455-608767B7-C183-4545-8672-45DEB64A1F45Q31057366-5406C22E-4E96-4D3D-95D9-81F122B1967FQ33689901-FB964B53-B743-4B65-A442-8005B8DA6192Q33753722-77D60AE8-A8F2-4D24-A245-D20278DCBE73Q33775399-3E25BB77-520A-4DD7-81C9-73FF07007C99Q33886464-5E833E22-6066-4F64-830F-576B3654AC5BQ33967649-1B95D0F5-8BF4-4B88-9063-36DA7DFAB9F3Q34141193-FC573626-EBE0-4633-8F92-491A7707CFFAQ34255935-3AFAA438-1838-45EA-A23B-89590627C6F0Q34306100-B356F8FB-8DC0-4883-A878-32DBDFC5F469Q34383765-401B12CA-C1E9-4308-B5BB-9057417B7512Q34527573-F4871F38-20A1-47B8-BC16-1A121C0C853EQ34915905-99353AD7-25AD-41CE-82D4-04A12D9F3012Q35083960-9B68F0BD-D1A6-4D70-A3DA-4644F1289C54Q35098322-31686EF7-EC4B-4047-81E3-A13D1418A547Q35432484-63A9FF8F-80E9-41A1-A107-4FE059CBB11AQ35541916-D6367860-E9C0-4993-92B2-81CE5C461895Q35627159-D7DA3F8E-56B1-4382-B68D-877841C3E473Q35825800-ABCE3BA4-5645-4ACB-8E53-5EAA615F0350Q36202855-F5C0493E-53B3-44B3-A3F7-3C64A67E3064Q36235704-A5E6B907-D8D9-43EC-B93C-910DE5C6724CQ36516936-06D1B70B-4B2A-4DC3-B535-7524E5A89B6AQ36569090-4164FCD8-2E9E-4CD1-AA5E-69A3B4456256Q36584224-C9184E45-EBCF-46C2-B7C3-DCE00E805C83Q36814830-665E10F4-BD91-4B98-9526-083A2D8A5A26Q37015715-09561504-51F9-4E48-85A7-CA0274D22E3EQ37237361-0367D15A-AD4A-4272-824C-AEC128F2D135Q37282793-90262A22-C1B5-4FA7-A877-317101452840Q37289236-DE818A7A-6580-4766-8039-EA3F318A6DBAQ37809862-C53920CD-08A9-4067-88A3-595060EA40F1Q37902873-63A8A313-C897-4F13-B646-6A76D088E808Q37903909-E48A143F-6CCE-48F3-8074-C3C9F42726EAQ37948702-45505F1E-715F-46F7-AC90-FFDB5F9D68E1Q37962840-A4D9025C-1ABE-49B1-B1E8-EE8BB71D5A7FQ38055496-C9C03785-F6C8-4008-9BE6-D8B4198D61B9Q38401259-8379F60F-8855-4C99-BC34-32AD9A0B755CQ38602875-82A58BE6-8F06-411E-BECD-63C248BA649BQ38739241-AEC14EC1-D3B6-4E1E-B50A-786F1BFAA580
P2860
Evaluation of early and late toxicities in chemoradiation trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Evaluation of early and late toxicities in chemoradiation trials.
@en
type
label
Evaluation of early and late toxicities in chemoradiation trials.
@en
prefLabel
Evaluation of early and late toxicities in chemoradiation trials.
@en
P356
P1476
Evaluation of early and late toxicities in chemoradiation trials
@en
P2093
Andrea Trotti
P304
P356
10.1200/JCO.2007.13.3983
P407
P577
2007-09-01T00:00:00Z